COMMUNIQUÉS West-GlobeNewswire

Mixie Technologies, Inc. (OTC: MIXE) Completes Corporate Rebranding and Trading Symbol Change
15/07/2026
Mixie Technologies focuses on acquiring companies and intellectual property built on unique, application-focused technology designed to deliver an advantage to customers, then scales them with AI-driven engineering [...]
SBC Medical to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:30 a.m. ET
15/07/2026
IRVINE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range [...]
The Coalition for Physician & APP Well-Being Launches “The Initiative Intelligence Guide” to Help Health Systems Better Evaluate Workforce, Retention, and Operational Initiatives
15/07/2026
The Coalition and American Hospital Association, AdventHealth, Atalan, and Providence’s Well Being Trust collaborate on practical framework for healthcare initiative evaluation ALTAMONTE SPRINGS, Fla., July 15, 2026 ( [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
15/07/2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, [...]
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
15/07/2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company [...]
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
15/07/2026
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data [...]
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
15/07/2026
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus 1 If approved, Gazyva/Gazyvaro will be the [...]
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
15/07/2026
Strong U.S. demand and new product launches drive first-half sales in Human Pharma Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches Positive Phase III data for survodutide and pipeline [...]
WONDERLAB Spotlights Gut Health and Innate Immunity, Featuring Its Proprietary Strain GOLDGUT-M520
15/07/2026
SHENZHEN, China, July 15, 2026 (GLOBE NEWSWIRE) -- On May 21, 2026, WONDERLAB ran a public science-education series on gut health and immunity, featuring its proprietary strain GOLDGUT-M520. The program included an [...]
Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach
15/07/2026
7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculature New non-human primate data demonstrate favorable [...]
45,611 Orion Corporation A shares converted into B shares
15/07/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JULY 2026 at 9.00 EEST 45,611 Orion Corporation A shares converted into B shares In accordance with [...]
Closing of Previously Announced Restructuring Transaction in Connection with CCAA Proceedings
15/07/2026
MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, in connection with the restructuring proceedings initiated on June 23, 2026 [...]
CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population
15/07/2026
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity Lehi, Utah, July 14, 2026 (GLOBE [...]
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
15/07/2026
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
15/07/2026
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Spire Healthcare announced as exclusive Team GB Official Healthcare Services Partner
15/07/2026
Organisations join forces for “a healthier, more productive nation” Agreement with Team GB covers the Los Angeles 2028 Olympic Games LONDON, July 15, 2026 (GLOBE NEWSWIRE) -- Spire Healthcare today announces a new [...]
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
14/07/2026
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
14/07/2026
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 [...]
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
14/07/2026
REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with palbociclib and [...]

Pages